Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | FFAR2 | O15552 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11385050 | 0.92 | ACE (0.61) | ACEHSD17B10FFAR2POLBGAA | |
| SCHEMBL683637 | 0.90 | ACE (0.67) | ACEHSD17B10FFAR2POLBGAA | |
| SCHEMBL11062771 | 0.90 | ACE (0.67) | ACEHSD17B10FFAR2POLBGAA | |
| SCHEMBL11190530 | 0.88 | ACE (0.62) | ACEHSD17B10FFAR2POLBGAA | |
| SCHEMBL11059109 | 0.88 | ACE (0.65) | ACEHSD17B10FFAR2POLBGAA | |
| SCHEMBL10939993 | 0.88 | ACE (0.57) | ACEHSD17B10FFAR2POLBGAA | |
| SCHEMBL11257852 | 0.85 | ACE (0.55) | ACEHSD17B10FFAR2POLBGAA | |
| SCHEMBL683282 | 0.85 | GAA (0.70) | ACEHSD17B10FFAR2POLBGAA | |
| SCHEMBL683176 | 0.85 | ACE (0.58) | ACEHSD17B10FFAR2POLBGAA | |
| Rentiapril SCHEMBL294980 | 0.85 | ACE (1.00) | ACEHSD17B10FFAR2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | ACE 4514/4885HSD17B10 3423/4885FFAR2 1345/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | ACE 6/4885HSD17B10 2865/4885FFAR2 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.